Kamada (NASDAQ:KMDA) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Kamada (NASDAQ:KMDA) issued its earnings results on Monday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01), Zacks reports. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The company had revenue of $47.01 million during the quarter, compared to analyst estimates of $154.21 million. Kamada updated its FY 2025 guidance to EPS.

Kamada Trading Up 3.9%

NASDAQ KMDA opened at $7.34 on Wednesday. The business’s 50-day moving average price is $6.89 and its 200 day moving average price is $7.08. Kamada has a twelve month low of $5.54 and a twelve month high of $9.15. The company has a market capitalization of $421.80 million, a PE ratio of 21.47, a price-to-earnings-growth ratio of 0.70 and a beta of 0.81.

Hedge Funds Weigh In On Kamada

A number of large investors have recently bought and sold shares of KMDA. Jane Street Group LLC acquired a new position in Kamada in the first quarter valued at $582,000. Goldman Sachs Group Inc. purchased a new stake in Kamada during the first quarter worth approximately $497,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Kamada in the second quarter worth $472,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kamada during the 1st quarter valued at $206,000. Finally, Jump Financial LLC acquired a new position in shares of Kamada during the 2nd quarter valued at $219,000. Hedge funds and other institutional investors own 20.38% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Kamada currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.